Table 1.

κ Statistics and Percent Agreement Values for Selected Data Abstraction Items (N = 132 Charts)

		Percent Agreement
Item Abstracted	κ (95% CI)	Observed	Expected^a
ASA= acetylsalicylic acid (aspirin); CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; HbA_1c=hemoglobin A_1c; TIA = transient ischemic attack.
^a Percent agreement expected (p_e) is a measure of the agreement that is expected to occur by chance between the raters.
^b Measurement period was the 12 months before first date of abstraction.
^c β-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker.
^d β-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, diuretic, calcium channel blocker.
Diagnoses
Cardiovascular disease	0.92 (0.85–0.99)	96.2	0.53
Chronic kidney disease	0.72 (0.58–0.87)	90.9	0.67
Diabetes	0.89 (0.82–0.97)	94.7	0.50
Dyslipidemia	0.90 (0.81–1.00)	97.0	0.69
Hypertension	0.80 (0.67–0.92)	93.2	0.66
Peripheral vascular disease	0.79 (0.62–0.97)	96.2	0.82
Stroke/TIA	0.89 (0.77–1.00)	97.7	0.79
Quality of care indicators^b
1 blood pressure recorded	1.00 (1.00–1.00)	100.0	0.87
1 HbA_1c test ordered	0.87 (0.78–0.96)	93.9	0.54
ASA recommended	0.83 (0.74–0.93)	91.7	0.33
CVD medications^c recommended	0.85 (0.76–0.94)	92.4	0.50
eGFR test ordered	0.74 (0.62–0.87)	90.2	0.62
Fasting blood glucose test ordered	0.70 (0.56–0.84)	88.6	0.63
Glycemic control medications recommended	0.83 (0.75–0.92)	90.9	0.45
Hypertension medications^d recommended	0.79 (0.68–0.90)	90.2	0.54
Lipid profile test ordered	0.71 (0.58–0.83)	87.1	0.56
Lipid-lowering medications recommended (statin or other)	0.79 (0.68–0.90)	90.9	0.57
Smoking status recorded	0.75 (0.63–0.88)	90.2	0.60
Smoking cessation counseling	0.88 (0.77–0.98)	96.2	0.69
Smoking cessation medication	0.88 (0.77–0.98)	96.2	0.70
Smoking cessation program referral	0.87 (0.77–0.98)	96.2	0.70
Waist circumference measured	0.00 (0.00–0.00)	95.5	0.95
Weight management program referral	0.86 (0.74–0.97)	95.5	0.68